Our findings suggest that PSME1 and PSME2 may be potential prognostic markers for enhancing survival and prognostic accuracy in GC patients and may even act as potential biomarkers for GC patients, indicating a response to immunotherapy. Here, PSME2 is linked to gastric cancer.